Olema Pharmaceuticals Inc
OLMA5.205USD
-0.125-2.35%
交易中 （美東）報價延遲15分鐘
355.67M總市值
虧損本益比TTM
關於 Olema Pharmaceuticals Inc 公司
Olema Pharmaceuticals, Inc. 是一家臨牀階段的生物製藥公司。該公司專注於發現、開發和商業化針對女性癌症的靶向療法。其主要候選產品 OP-1250 是一種口服療法，具有作爲完全雌激素受體 (ER) 拮抗劑 (CERAN) 和選擇性 ER 降解劑 (SERD) 的綜合活性。該公司的 OP-1250 是一種口服小分子臨牀階段候選產品，用於治療內分泌驅動的癌症。OP-1250 作爲單一療法以及與細胞週期依賴性激酶 4 和 6 (CDK4/6) 抑制劑聯合使用，在幾種異種移植模型中表現出明顯的腫瘤縮小效果，包括 ESR1 和 PIK3CA 突變和中樞神經系統 (CNS) 轉移。目前該藥物處於 I/II 期臨牀試驗階段，且處於 Ib/II 期臨牀試驗階段，與 palbociclib 聯合用於治療轉移性 ER 陽性 (ER+)、人類表皮生長因子受體 2 陰性 (HER2-) 乳腺癌患者。
公司簡介
公司代碼OLMA
公司名稱Olema Pharmaceuticals Inc
上市日期Nov 19, 2020
CEOMr. Sean P. Bohen, M.D., Ph.D.
員工數量96
證券類型Ordinary Share
年結日Nov 19
公司地址780 Brannan Street
城市SAN FRANCISCO
上市交易所NASDAQ Global Select Consolidated
國家United States of America
郵編94103
電話14156513316
網址https://olema.com/
公司代碼OLMA
上市日期Nov 19, 2020
CEOMr. Sean P. Bohen, M.D., Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Mr. David C. Myles, Ph.D.
Mr. David C. Myles, Ph.D.
Chief Discovery and Non-Clinical Development Officer
Chief Discovery and Non-Clinical Development Officer
586.38K
+4.02%
Mr. Andrew Rappaport
Mr. Andrew Rappaport
Independent Director
Independent Director
385.96K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
83.88K
--
Ms. Shawnte M. Mitchell
Ms. Shawnte M. Mitchell
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Naseem Zojwalla, M.D.
Dr. Naseem Zojwalla, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Ian Clark
Mr. Ian Clark
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Sean P. Bohen, M.D., Ph.D.
Mr. Sean P. Bohen, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Shane Kovacs
Mr. Shane Kovacs
Chief Operating and Financial Officer
Chief Operating and Financial Officer
--
--
Dr. Gorjan Hrustanovic, Ph.D.
Dr. Gorjan Hrustanovic, Ph.D.
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. David C. Myles, Ph.D.
Mr. David C. Myles, Ph.D.
Chief Discovery and Non-Clinical Development Officer
Chief Discovery and Non-Clinical Development Officer
586.38K
+4.02%
Mr. Andrew Rappaport
Mr. Andrew Rappaport
Independent Director
Independent Director
385.96K
--
Ms. Cynthia M. Butitta
Ms. Cynthia M. Butitta
Independent Director
Independent Director
83.88K
--
Ms. Shawnte M. Mitchell
Ms. Shawnte M. Mitchell
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Graham L. Walmsley, M.D., Ph.D.
Dr. Graham L. Walmsley, M.D., Ph.D.
Independent Director
Independent Director
--
--
Dr. Naseem Zojwalla, M.D.
Dr. Naseem Zojwalla, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Bain Capital Life Sciences Investors, LLC
10.00%
Paradigm BioCapital Advisors LP
9.85%
BVF Partners L.P.
7.74%
Deep Track Capital LP
5.03%
BlackRock Institutional Trust Company, N.A.
4.85%
Other
62.52%
持股股東
持股股東
佔比
Bain Capital Life Sciences Investors, LLC
10.00%
Paradigm BioCapital Advisors LP
9.85%
BVF Partners L.P.
7.74%
Deep Track Capital LP
5.03%
BlackRock Institutional Trust Company, N.A.
4.85%
Other
62.52%
股東類型
持股股東
佔比
Hedge Fund
33.03%
Investment Advisor
28.42%
Investment Advisor/Hedge Fund
23.72%
Venture Capital
9.71%
Individual Investor
4.18%
Research Firm
3.71%
Bank and Trust
0.08%
Pension Fund
0.03%
Insurance Company
0.02%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
320
70.41M
102.91%
-12.31M
2025Q1
327
72.74M
106.44%
-11.08M
2024Q4
313
78.82M
113.63%
+3.60M
2024Q3
301
63.64M
110.87%
-10.05M
2024Q2
299
62.60M
111.72%
-7.29M
2024Q1
288
60.06M
107.83%
-1.82M
2023Q4
271
55.06M
100.31%
-2.15M
2023Q3
263
50.27M
92.75%
-945.85K
2023Q2
259
39.52M
96.98%
-9.43M
2023Q1
256
36.49M
89.86%
-12.60M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Bain Capital Life Sciences Investors, LLC
6.84M
10%
+2.44M
+55.54%
Mar 31, 2025
Paradigm BioCapital Advisors LP
6.74M
9.85%
-563.80K
-7.72%
Mar 31, 2025
BVF Partners L.P.
5.30M
7.74%
--
--
Mar 31, 2025
Deep Track Capital LP
3.44M
5.03%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.32M
4.85%
+40.22K
+1.23%
Mar 31, 2025
Logos Global Management LP
3.21M
4.69%
--
--
Apr 21, 2025
Franklin Advisers, Inc.
3.01M
4.4%
+2.74M
+1000.44%
Mar 31, 2025
MPM BioImpact LLC
2.93M
4.28%
+17.90K
+0.61%
Mar 31, 2025
The Vanguard Group, Inc.
2.87M
4.2%
+193.65K
+7.23%
Mar 31, 2025
Lightspeed Venture Partners
1.93M
2.82%
--
--
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.94%
ALPS Medical Breakthroughs ETF
0.2%
iShares Micro-Cap ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.03%
Invesco Nasdaq Biotechnology ETF
0.03%
iShares Biotechnology ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Schwab U.S. Small-Cap ETF
0.01%
ProShares UltraPro Russell2000
0.01%
Global X Russell 2000 ETF
0.01%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.94%
ALPS Medical Breakthroughs ETF
佔比0.2%
iShares Micro-Cap ETF
佔比0.06%
ProShares Ultra Nasdaq Biotechnology
佔比0.03%
Invesco Nasdaq Biotechnology ETF
佔比0.03%
iShares Biotechnology ETF
佔比0.02%
iShares Russell 2000 Value ETF
佔比0.02%
Schwab U.S. Small-Cap ETF
佔比0.01%
ProShares UltraPro Russell2000
佔比0.01%
Global X Russell 2000 ETF
佔比0.01%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
